Compare LEG & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEG | ARDX |
|---|---|---|
| Founded | 1883 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2018 | 2014 |
| Metric | LEG | ARDX |
|---|---|---|
| Price | $11.19 | $5.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $10.50 | ★ $15.14 |
| AVG Volume (30 Days) | 2.5M | ★ 4.2M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | ★ 145.31 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $5,203,900,000.00 | $2,607,000.00 |
| Revenue This Year | N/A | $37.75 |
| Revenue Next Year | $2.73 | $34.24 |
| P/E Ratio | $75.71 | ★ N/A |
| Revenue Growth | ★ 1.37 | N/A |
| 52 Week Low | $7.86 | $4.08 |
| 52 Week High | $13.00 | $8.40 |
| Indicator | LEG | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.98 | 36.58 |
| Support Level | $10.72 | $4.95 |
| Resistance Level | $11.42 | $5.34 |
| Average True Range (ATR) | 0.42 | 0.19 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 57.69 | 9.49 |
Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the maximum of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.